Completed PHASE3 INTERVENTIONAL 3-arm NCT00471705

Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.

Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.

Sponsor: Dirección de Sanidad del Ejército de Colombia (DISAN)

Conditions Cutaneous Leishmaniasis

Interventions Glucantime® Miltefosine Thermotherapy

Updated 8 times since 2017 Last updated: Jul 27, 2018 Started: Jun 30, 2006 Primary completion: Aug 31, 2008 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cutaneous Leishmaniasis and is currently completed. Dirección de Sanidad del Ejército de Colombia (DISAN) leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Feb 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Feb 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dirección de Sanidad del Ejército de Colombia (DISAN)
Ministerio de Salud y Protección Social, Colombia
Universidad de Antioquia

Data source: Universidad de Antioquia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Medellín, Colombia